Semaglutide vs Tirzepatide: Which Is Right for You?

Ask anyone researching medical weight loss right now and the same two names surface: semaglutide and tirzepatide. Both are once-weekly injections, both quiet appetite through gut-hormone signaling, and both produced results in clinical trials that older weight loss medications never approached. They are still meaningfully different drugs. At InnerWorks: Performance & Wellness in St. Augustine, choosing between them is one of the most frequent conversations inside our weight loss peptide program, so this is the comparison we actually walk patients through.

One ground rule before the details: no article can tell you which medication you should take. Your health history, labs, goals, tolerance, and current availability all shape the answer, which is why we review the options together at your consultation instead of naming a medication sight unseen. What a comparison can do is prepare you to have that conversation well.

How Each Medication Works

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after you eat, which slows stomach emptying, dampens appetite signaling in the brain, and supports a steadier insulin response. For most patients the practical effect is that portions shrink without a fight and the constant pull toward snacking fades. Our semaglutide page covers the medication in depth, and MedlinePlus maintains a plain-language profile of it.

Tirzepatide keeps that mechanism and adds a second target. It activates both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide), a pairing researchers call dual agonism. The added GIP activity appears to strengthen the overall metabolic effect, which is one reason its trial numbers ran higher. You can read more on our tirzepatide page or in the corresponding MedlinePlus entry.

What the Landmark Trials Showed

The cleanest evidence comes from two large trials, each published in the New England Journal of Medicine. In STEP 1, adults with overweight or obesity who received weekly semaglutide alongside lifestyle support averaged roughly 15 percent body weight loss over 68 weeks. In SURMOUNT-1, participants taking tirzepatide averaged up to about 20 percent at the highest dose over 72 weeks.

Read those numbers with care. They come from separate studies with different designs and populations, not a direct head-to-head race, and averages hide a wide range of individual responses. Some patients respond strongly to semaglutide and would gain little by switching. Others plateau on GLP-1 therapy alone and do better with the dual mechanism. Trial figures set a reasonable expectation; they are not a personal guarantee.

Semaglutide vs Tirzepatide at a Glance

	Semaglutide	Tirzepatide
Mechanism	GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Schedule	Once-weekly injection	Once-weekly injection
Trial benchmark	Roughly 15% average loss in STEP 1 (68 weeks)	Up to about 20% average loss at the highest dose in SURMOUNT-1 (72 weeks)
Common side effects	Nausea, constipation, diarrhea, mostly around dose increases	Similar digestive profile, varying by dose
Titration	Gradual increases over several months	Gradual increases over several months
Track record	Longest history in weight management	Newer, with larger average trial losses

Side Effects: Similar Profiles, Personal Tolerance

Both medications share a digestive side-effect profile: nausea, constipation, diarrhea, and occasional vomiting, concentrated in the weeks after a dose increase and usually easing as the body adapts. Both also carry prescribing warnings your provider will review with you, including cautions around pancreatitis and a boxed warning based on thyroid tumor findings in rodent studies. That is a large part of why these are supervised prescriptions rather than products you simply buy.

Tolerance is individual. Some patients feel noticeably better on one medication than the other at an equivalent stage, and a supervised program has room to respond: slowing the titration, holding a dose, reinforcing hydration and protein intake, or revisiting the medication choice entirely.

Dosing and Supervised Titration

Neither drug starts at full strength. Each begins at a low weekly dose that steps up gradually over several months, giving your digestive system time to adjust. Most of the side-effect misery we hear about from patients who started elsewhere traces back to titration that moved too fast or was never adapted to the person. Supervision means the schedule bends to your response. Reaching the top dose is not the finish line; reaching the dose where you lose weight and feel well is.

What Each Costs, and Why the Answer Moves

Neither medication has a single price, and any clinic quoting one number without asking questions is simplifying too much. The real cost drivers are which medication and dose you land on (higher tirzepatide doses generally run more), whether a brand-name product or another formulation is appropriate and available, how your insurance treats weight management prescriptions, and what surrounds the injection itself: provider visits, body-composition tracking, nutrition guidance, and follow-up.

Sourcing matters just as much. The FDA has cautioned patients about unapproved compounded semaglutide products, and compounded availability shifts with market conditions, so where a medication comes from deserves the same scrutiny as its price. At InnerWorks, either medication sits inside a supervised program with package and membership options that bundle the oversight in, and the exact figures for your plan are confirmed at your consultation.

Who Tends to Fit Which

Patterns we see in practice, offered as tendencies rather than rules:

• Semaglutide tends to suit patients who want the option with the longest track record in weight management, those with moderate weight loss goals, and situations where coverage or budget favors it.
• Tirzepatide tends to suit patients with more total weight to lose, those who plateaued on GLP-1 therapy alone, and some patients whose blood sugar picture makes the dual mechanism worth discussing with their provider.
• Neither is appropriate for certain histories, including some thyroid and pancreatic conditions and pregnancy, which is screened for before anything is prescribed.

If weight loss resistance has been your pattern, medication is one lever among several, and it works best when paired with the protein, activity, and sleep fundamentals summarized in resources like the MedlinePlus obesity overview.

Making the Call in St. Augustine

Living in coastal northeast Florida gives you year-round reasons to want the weight off, and no shortage of clinics offering these medications. The differentiator is not access to a drug name; it is whether someone qualified matches the drug, the dose, and the pace to you and then stays involved. A consultation at our St. Augustine clinic reviews your history and goals, walks through both medications honestly, and maps out the plan, including costs, before you commit. When you are ready, schedule a consultation and bring your questions.

Semaglutide and tirzepatide are prescription medications. Brand-name versions are FDA-approved for chronic weight management in specific patient populations; availability of any given formulation varies, and no specific medication is promised before a provider evaluation. Results differ by individual and depend on your clinical picture and adherence.